ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily TSLA Bull 1.5X Shares

GraniteShares 1.5x Long NVDA Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Bank Of Montreal

GraniteShares 1.25x Long Tesla Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

ProShares UltraShort Silver

VS TR 2x Long VIX Futures ETF

Direxion Daily FTSE China Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

Volatility Shares Trust 2x Ether ETF

T-REX 2X Inverse Tesla Daily Target ETF

MicroSectors Gold Miners 3X Leveraged ETN

ProShares Ultra Silver

United States Natural Gas

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

iShares Ethereum Trust ETF

iShares US Home Construction

Incannex Healthcare Limited American Depositary Shares

Innovative Eyewear Inc. Common Stock

Septerna Inc. Common Stock

HWH International Inc. Common Stock

Reddit Inc. Class A Common Stock

DevvStream Corp. Common Stock

Rigetti Computing Inc. Common Stock

ZK International Group Co. Ltd Ordinary Share

Oklo Inc.

Super Micro Computer Inc. Common Stock

Inno Holdings Inc. Common Stock

Gryphon Digital Mining Inc Common Stock

Next Technology Holding Inc. Ordinary Shares

Kindly MD Inc. Common Stock

Nuvve Holding Corp. Common Stock

Classover Holdings Inc. Class B Common Stock

Oriental Rise Holdings Limited Ordinary Shares

MicroAlgo Inc. Ordinary Shares

Hyperscale Data Inc. Common Stock

AgriFORCE  Growing Systems Ltd. Common Shares

Click here to get full coverage on MaxCyte, Inc. (MXCT): A Bull Case Theory - Insider Monkey

MaxCyte, Inc. (MXCT): A Bull Case Theory  Insider Monkey

MaxCyte, Inc. (MXCT): A Bull Case Theory - Insider Monkey

Click here to get full coverage on MaxCyte Sets Q1 Earnings Date: Key Financial Updates Coming May 7 - Stock Titan

MaxCyte Sets Q1 Earnings Date: Key Financial Updates Coming May 7  Stock Titan

MaxCyte Sets Q1 Earnings Date: Key Financial Updates Coming May 7 - Stock Titan

Click here to get full coverage on MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates  MSN

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN

Click here to get full coverage on MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know  Yahoo Finance

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Globe and Mail

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance  The Globe and Mail

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Globe and Mail

Click here to get full coverage on Insider Sale: CHIEF FINANCIAL OFFICER of $MXCT Sells 6,939 Shares - Nasdaq

Insider Sale: CHIEF FINANCIAL OFFICER of $MXCT Sells 6,939 Shares  Nasdaq

Insider Sale: CHIEF FINANCIAL OFFICER of $MXCT Sells 6,939 Shares - Nasdaq

Click here to get full coverage on MaxCyte Files Form 10-Q for Q1 2025 - TipRanks

MaxCyte Files Form 10-Q for Q1 2025  TipRanks

MaxCyte Files Form 10-Q for Q1 2025 - TipRanks

Click here to get full coverage on MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price  Seeking Alpha

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha

Click here to get full coverage on Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - simplywall.st

Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65?  simplywall.st

Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - simplywall.st

Click here to get full coverage on MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks

MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments  Technology Networks

MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks

Click here to get full coverage on Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround  Yahoo Finance

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript - Insider Monkey

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript  Insider Monkey

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - Stock Titan

MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8%  Stock Titan

MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - Stock Titan

Click here to get full coverage on MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks

MaxCyte Announces Change in Major Holdings by BlackRock  TipRanks

MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks

Click here to get full coverage on Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)  Yahoo Finance

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance

Click here to get full coverage on Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - Stock Titan

Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment  Stock Titan

Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - Stock Titan

Click here to get full coverage on With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns  Yahoo Finance

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance

Click here to get full coverage on BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com Nigeria

BTIG cuts MaxCyte stock price target to $5, maintains Buy rating  Investing.com Nigeria

BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com Nigeria

Click here to get full coverage on MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks

MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip  TipRanks

MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks

Click here to get full coverage on MaxCyte Awards Stock Options and Units to Executives - TipRanks

MaxCyte Awards Stock Options and Units to Executives  TipRanks

MaxCyte Awards Stock Options and Units to Executives - TipRanks

Click here to get full coverage on MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks

MaxCyte Announces CFO’s RSU Vesting and Share Sale  TipRanks

MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks

Click here to get full coverage on MaxCyte executives receive equity incentives - Investing.com

MaxCyte executives receive equity incentives  Investing.com

MaxCyte executives receive equity incentives - Investing.com

Click here to get full coverage on MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript  Insider Monkey

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks

BlackRock Increases Stake in MaxCyte to 7.66%  TipRanks

BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks

Click here to get full coverage on BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com Australia

BTIG cuts MaxCyte stock price target to $5, maintains Buy rating  Investing.com Australia

BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com Australia

Click here to get full coverage on Daily Stock Market Report (Tue 15 April 2025) - HFD, TBLD, BILN, BME, KOO, LIO, RNO, DLAR, RWA, IHP, EMAN, MXCT - Stockopedia

Daily Stock Market Report (Tue 15 April 2025) - HFD, TBLD, BILN, BME, KOO, LIO, RNO, DLAR, RWA, IHP, EMAN, MXCT  Stockopedia

Daily Stock Market Report (Tue 15 April 2025) - HFD, TBLD, BILN, BME, KOO, LIO, RNO, DLAR, RWA, IHP, EMAN, MXCT - Stockopedia

Click here to get full coverage on BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks

BlackRock Increases Stake in MaxCyte to 7.57%  TipRanks

BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks

Click here to get full coverage on MaxCyte Acquires Gene Editing Analytics Company SeQure Dx - marketscreener.com

MaxCyte Acquires Gene Editing Analytics Company SeQure Dx  marketscreener.com

MaxCyte Acquires Gene Editing Analytics Company SeQure Dx - marketscreener.com

Click here to get full coverage on MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews

MaxCyte reports a return to core revenue growth in FY24  DirectorsTalk Interviews

MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews

Click here to get full coverage on MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com

MaxCyte stock plunges to 52-week low of $2.25 amid market challenges  Investing.com

MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com

Click here to get full coverage on MaxCyte Acquires SeQure Dx - citybiz

MaxCyte Acquires SeQure Dx - citybiz

Click here to get full coverage on Art Mandell Retires from MaxCyte Board - citybiz

Art Mandell Retires from MaxCyte Board  citybiz

Art Mandell Retires from MaxCyte Board - citybiz

Click here to get full coverage on MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance  The Manila Times

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times

Click here to get full coverage on BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks

BlackRock Increases Stake in MaxCyte to 7.71%  TipRanks

BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks

Click here to get full coverage on MaxCyte Acquires SeQure Dx - FinSMEs

MaxCyte Acquires SeQure Dx - FinSMEs

Click here to get full coverage on MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks

MaxCyte Experiences Shift in Major Holdings by BlackRock  TipRanks

MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks

Click here to get full coverage on Greg Watson - Assistant Coach - Throws - Cowboy Cross Country & Track Coaches - Oklahoma State University Athletics

Greg Watson - Assistant Coach - Throws - Cowboy Cross Country & Track Coaches  Oklahoma State University Athletics

Greg Watson - Assistant Coach - Throws - Cowboy Cross Country & Track Coaches - Oklahoma State University Athletics

Click here to get full coverage on John Oliver - Assistant Coach - Distance - Cowboy Cross Country & Track Coaches - Oklahoma State University Athletics

John Oliver - Assistant Coach - Distance - Cowboy Cross Country & Track Coaches  Oklahoma State University Athletics

John Oliver - Assistant Coach - Distance - Cowboy Cross Country & Track Coaches - Oklahoma State University Athletics

Click here to get full coverage on MaxCyte: Building the Future of Cell and Gene Therapy Innovation - The Globe and Mail

MaxCyte: Building the Future of Cell and Gene Therapy Innovation  The Globe and Mail

MaxCyte: Building the Future of Cell and Gene Therapy Innovation - The Globe and Mail

Click here to get full coverage on MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - PR Newswire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market  PR Newswire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - PR Newswire

Click here to get full coverage on Rory Leonard - 2022-23 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Rory Leonard - 2022-23 - Cowboy Cross Country & Track  Oklahoma State University Athletics

Rory Leonard - 2022-23 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Click here to get full coverage on MaxCyte signs strategic platform license with biotech - Proactive Investors

MaxCyte signs strategic platform license with biotech  Proactive Investors

MaxCyte signs strategic platform license with biotech - Proactive Investors

Click here to get full coverage on Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard (NYSE:LAZ), Amylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard (NYSE:LAZ), Amylyx Pharmaceuticals (NASDAQ:AMLX)  Benzinga

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard (NYSE:LAZ), Amylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga

Click here to get full coverage on Joshua Anadu - 2019-20 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Joshua Anadu - 2019-20 - Cowboy Cross Country & Track  Oklahoma State University Athletics

Joshua Anadu - 2019-20 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Click here to get full coverage on Blake Scott - 2019-20 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Blake Scott - 2019-20 - Cowboy Cross Country & Track  Oklahoma State University Athletics

Blake Scott - 2019-20 - Cowboy Cross Country & Track - Oklahoma State University Athletics

Click here to get full coverage on MaxCyte - Pole Position in Cell and Gene Therapy - Proactive Investors

MaxCyte - Pole Position in Cell and Gene Therapy  Proactive Investors

MaxCyte - Pole Position in Cell and Gene Therapy - Proactive Investors

Click here to get full coverage on Major announcements for MaxCyte - Proactive financial news

Major announcements for MaxCyte  Proactive financial news

Major announcements for MaxCyte - Proactive financial news

Click here to get full coverage on Fig. 1. (a) Core sample containing intact roots and soil collected... - ResearchGate

Fig. 1. (a) Core sample containing intact roots and soil collected...  ResearchGate

Fig. 1. (a) Core sample containing intact roots and soil collected... - ResearchGate

Click here to get full coverage on MaxCyte launches latest iteration of its Flow Electroporation cell editing technology - Proactive Investors

MaxCyte launches latest iteration of its Flow Electroporation cell editing technology  Proactive Investors

MaxCyte launches latest iteration of its Flow Electroporation cell editing technology - Proactive Investors

Click here to get full coverage on William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT) - Defense World

William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT)  Defense World

William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT) - Defense World

Click here to get full coverage on Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT)  Defense World

Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Click here to get full coverage on Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT)  Defense World

Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Click here to get full coverage on MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World

MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co.  Defense World

MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World

Click here to get full coverage on Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT)  Defense World

MXCT

Price Chart

Key Statistics

Technicals

About MXCT

Latest News

MaxCyte, Inc. (MXCT): A Bull Case Theory - Insider Monkey

MaxCyte Sets Q1 Earnings Date: Key Financial Updates Coming May 7 - Stock Titan

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN

Advanced Charts

Top Gainers

Top Losers